GlassScriptPhysician profile
Stephen D Reinhardt
NPI 1437101250
$3,264.48
in general payments reported to CMS, 2019-2025
44 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $695 · 2021: $401 · 2022: $561 · 2023: $217 · 2024: $351 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $324.91 | 2019-2025 | |
| Amgen INC. | $324.32 | 2019-2025 | Prolia, Evenity |
| Allergan, INC. | $307.49 | 2019-2020 | |
| Abbvie INC. | $251.16 | 2019-2023 | |
| Medicure Pharma INC. | $216.87 | 2020-2021 | |
| Lilly USA, LLC | $189.53 | 2019-2024 | Kisunla |
| Astrazeneca Pharmaceuticals LP | $173.04 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $135.51 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $106.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.64 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $67.18 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $64.54 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.42 | 2022 | |
| Glaxosmithkline, LLC. | $62.90 | 2019-2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $59.63 | 2019-2021 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Reinhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.